Skip to content
Home/Companies/Biotech/Olink Proteomics

Olink Proteomics

Biotech·Sweden·Exited 2021·Held 2yr
Entry
2019
Hold
2yr
Exit
2021

Who owns Olink Proteomics?

Olink Proteomics is a Swedish Biotech company, formerly owned by Summa Equity, exited in 2021 (exit via IPO). No current private equity owner is on file.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Summa Equity
Investor
Summa Equity
Summa Equity Fund II · 2019 · Buyout

Key facts

HQSweden
SectorBiotech
StatusAcquired
Exit Type
IPO
Exit Year
2021

More from Summa Equity Fund II

Other portfolio companies in the same fund.

Axion Biosystems
Active
MedTechUS· 2021
G-CON Manufacturing
Exited 2025
HealthcareUS· 2021
to Bridgepoint
Holdbart
Active
ConsumerNorway· 2021
myneva
myneva
Active
SaaSGermany· 2021
Nofitech
Active
IndustrialsNorway· 2021
Sengenics
Active
BiotechSingapore· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Olink Proteomics?

Olink Proteomics was formerly owned by Summa Equity, exited in 2021. No current private equity owner is on file.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue